Evidence map›Paper›PMID 37333850›Full record

ReviewFrontiers in cellular and infection microbiology2023

Intestinal bacteria-a powerful weapon for fungal infections treatment.

Liu Cong, Chaoqun Chen, Shanshan Mao, Zibing Han, Zuobin Zhu, Ying Li

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in cellular and infection microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Review
  3. Current and emerging approaches to manage chronic inflammatory gut disorders.Frontiers in cellular and infection microbiology · 2026
    Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Connecting Cryptococcal Meningitis and Gut Microbiome.International journal of molecular sciences · 2023
    Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Liu CongSchool of Medical Technology, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Chaoqun ChenSchool of Medical Technology, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Shanshan MaoSchool of Medical Technology, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Zibing HanDepartment of Genetics, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Zuobin ZhuDepartment of Genetics, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Ying LiSchool of Medical Technology, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Xuzhou Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The morbidity and mortality of invasive fungal infections are rising gradually. In recent years, fungi have quietly evolved stronger defense capabilities and increased resistance to antibiotics, posing huge challenges to maintaining physical health. Therefore, developing new drugs and strategies to combat these invasive fungi is crucial. There are a large number of microorganisms in the intestinal tract of mammals, collectively referred to as intestinal microbiota. At the same time, these native microorganisms co-evolve with their hosts in symbiotic relationship. Recent researches have shown that some probiotics and intestinal symbiotic bacteria can inhibit the invasion and colonization of fungi. In this paper, we review the mechanism of some intestinal bacteria affecting the growth and invasion of fungi by targeting the virulence factors, quorum sensing system, secreting active metabolites or regulating the host anti-fungal immune response, so as to provide new strategies for resisting invasive fungal infection.

Indexed as

MycosesAnimalsAntifungal AgentsBacteriaFungiHumansIntestinesMammalsSymbiosisAntifungal Agentsactive metabolitesantifungalfungal resistanceprobioticstoxicity factor

Identifiers

PMID37333850
PMCPMC10272564
OpenAlexW4379231354

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.